Deciphera reports Q4 EPS (54c), consensus (58c)

Reports Q4 revenue $48.3M, consensus $ $45.92M. Recorded $46.7M in QINLOCK net product revenue in the fourth quarter of 2023, including $35.3M in U.S. net product revenue and $11.4 M in international net product revenue, an increase of 42% from net product revenue of $32.9 M in the fourth quarter of 2022. “We are proud of the significant progress we made across our company throughout 2023, particularly in our late-stage programs as we continue on our path to becoming a self-sustaining, fully integrated biotechnology company. I am excited to announce another record quarter of QINLOCK revenue, demonstrating the proven commercial capabilities that position us well as we continue to evolve into a company with multiple approved medicines,” said Steve Hoerter, President and Chief Executive Officer of Deciphera Pharmaceuticals. “Looking ahead, we plan to build upon this momentum in 2024 as we work to file regulatory submissions for vimseltinib, which has the potential to be a much-needed treatment option for patients with tenosynovial giant cell tumor, continue enrollment of our INSIGHT Phase 3 study of QINLOCK, and progress our early-stage pipeline of potential first- or best-in-class candidates.”